Skip to main content
. 2013 Aug 19;14:261. doi: 10.1186/1745-6215-14-261

Figure 5.

Figure 5

ADAPT HER2+/HR- trial design. HER2+/HR- patients receive either dual anti-HER2 blockade with Trastuzumab and Pertuzumab or dual anti-HER2 blockade with Trastuzumab and Pertuzumab and chemotherapy backbone with Paclitaxel for induction therapy, which is subject to randomization. Randomization is only applicable after HR and HER2 status are confirmed by central pathology. The randomized regimen is applied in the neoadjuvant setting for twelve weeks followed by surgery.